Clinical Treatment Research of Acute Myeloid Leukemia (AML)

Dear Colleagues,

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, which presents approximately 20,000 new cases in the USA each year. Recently, despite the FDA approving several new targeted therapies for this disease, its five-year overall survival remains low, at around 30%. Additionally, the main curative therapies, namely intensive chemotherapy and allogeneic stem cell transplant, can be severely toxic and unsafe in older populations. The main limitations in AML-directed therapy are due to the heterogeneity of the disease and the, on average, older age of patients at diagnosis. New combination therapies with approved agents are being tested, but there remains an unmet need for novel treatment strategies. The characterization of the clonal population of myeloblasts using newer technologies such as single-cell sequencing, and the improved understanding of resistance mechanisms from the blasts as well as the surrounding microenvironment, have opened up new avenues for treatment approaches.

Manuscripts welcome to be submitted to this Special Issue include original research papers or reviews that focus on recent advances and the future challenges in the treatment of AML.

Dr. Madelyn Burkart
Dr. Sara Small
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.